Biopharma dive · 13h ago
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.
Read the full story at Biopharma dive →